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ABSTRACT 
Purpose: The purpose of this Doctor of Nursing Practice study was to investigate the prevalence 
of metabolic complications as well as recurrent or new-onset non-alcoholic fatty liver disease 
(NAFLD) and associated cardiovascular disease risk among liver transplant recipients. 
Design: Retrospective, descriptive. 
Setting: Local transplant program in San Antonio, Texas. 
Sample: 41 liver transplant recipients transplanted between July 2016 and June 2017. 
Methods: A health care record review using a data collection instrument created to profile 
cardiovascular disease risk up to one-year post-transplant. 
Main Research Variables: Cardiovascular disease risk factors including blood pressure (BP), 
hemoglobin A1C, low-density lipoprotein, and body mass index, as well as NAFLD.  
Additional Research Variables: Variables influencing NAFLD and cardiovascular disease risk 
such as etiology of liver disease, ethnicity, age, gender, family history, and immunosuppression 
medications. 
Findings: Most data on metabolic complications and cardiovascular disease risk factors such as 
dyslipidemia and diabetes mellitus were not documented. Hypertension was prevalent at one-
year post-transplant, and BPs were sub-optimally managed. New-onset or recurrent NAFLD 
following transplant only occurred in 12% of the sample. There were no documented 
cardiovascular disease related events within the first year following transplant.  
Conclusions: Prevalence of metabolic complications as well as NAFLD among liver transplant 
recipients is important in the evaluation of cardiovascular disease risk to reduce related events 
and mortality following transplant but not commonly documented by the local transplant 
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program. Improved documentation and communication between Hepatology specialists and 
primary care providers is necessary for early recognition and appropriate medical management of 
post-transplant metabolic complications. Better control of BP may help reduce cardiovascular 
disease risk in the late post-transplant period. Prospective studies with larger sample sizes are 
needed to further investigate the prevalence of metabolic complications as well as NAFLD and 
associated cardiovascular disease risk among liver transplant recipients. 
Key Words: cardiovascular disease risk; liver transplant; metabolic complications; non-
alcoholic fatty liver disease 
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INTRODUCTION 
This Doctor of Nursing Practice (DNP) study investigates the prevalence of metabolic 
complications among liver transplant recipients at a local transplant program in San Antonio, 
Texas. The study provides insight into the most recent practice guidelines on the appropriate 
medical management of obesity, dyslipidemia, diabetes mellitus, and hypertension as poor 
control can lead to an increased risk of cardiovascular disease and associated events following 
transplant. In addition, the prevalence of recurrent or new-onset non-alcoholic fatty liver disease 
(NAFLD) is explored as this disease coincides with the development of metabolic complications. 
The study data serves as a foundation for future improvement strategies to optimize the medical 
management of post-transplant metabolic complications. Early recognition and appropriate 
treatment of metabolic complications may help reduce the prevalence of recurrent or new-onset 
NAFLD as well as associated cardiovascular disease risk following transplant leading to an 
enhanced quality and quantity of life for liver transplant recipients. 
Background Knowledge 
Liver transplantation has become the leading treatment for patients diagnosed with acute 
liver failure and advanced liver disease or cirrhosis (Barnard, Konyn, & Saab, 2016; Pisano et 
al., 2016). Significant improvements in immunosuppression medications, screening of transplant 
candidates as well as donor organs, and surgical techniques since the time of the first human 
liver transplant have resulted in increased survival rates among liver transplant recipients 
(Barnard et al., 2016; Brunault et al., 2015; Haugen et al., 2018; Martin et al., 2014; Pisano et al., 
2016; Song et al., 2014). Survival rates among this population have reached as high as over 90% 
and 80% at one- and five-years’ post-transplant, respectively (Jimenez-Perez, Gonzalez-Grande, 
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Guzman, Trill, & Lopez, 2016; Organ Procurement and Transplant Organization, 2019). Thus, 
post-transplant metabolic complications and cardiovascular disease impacting longevity 
following transplant have gained increased attention. 
Metabolic complications including obesity, dyslipidemia, diabetes mellitus, and 
hypertension are exceedingly prevalent following transplant and are associated with increased 
cardiovascular disease risk (Barnard et al., 2016; Brunault et al., 2015; Fussner et al., 2015; 
Glowczynska et al., 2018; Jimenez-Perez et al., 2016; Marjot et al., 2018; Pisano et al., 2016; 
Wang, Yu, & Chan, 2016). Estimated prevalence rates throughout the literature are outlined in 
Table 1 and surpass that of the general population making cardiovascular disease a leading cause 
of morbidity and mortality among liver transplant recipients (Barnard et al., 2016; Gallegos-
Orozco & Charlton, 2017; Jimenez-Perez et al., 2016; Konerman et al., 2017). 
TABLE 1. Prevalence of cardiovascular disease risk factors in liver transplant recipients. 
Cardiovascular Disease Risk Factor Estimated Prevalence 
Hypertension 40% - 85% 
Diabetes Mellitus 10% - 38% 
Obesity 25% - 54% 
Dyslipidemia 45% - 71% 
Approximately 40% of deaths following transplant, not associated with allograft 
dysfunction, have been attributed to cardiovascular disease (Jimenez-Perez et al., 2016; Maurice 
& Manousou, 2018). Research by Fussner et al. (2015) further determined that 10.6% of liver 
transplant recipients developed a cardiovascular disease related event such as a myocardial 
infarction, stroke, peripheral vascular disease, or coronary artery disease within the first year 
following transplant. The number of cardiovascular disease related deaths has been shown to 
increase in the long-term and is noted to be over 20% at three-years of survival (Barnard et al., 
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2016). Metabolic complications as well as NAFLD prior to transplant are considered risk factors 
highly associated with the development of cardiovascular disease related events following 
transplant (Jimenez-Perez et al. 2016; Pisano et al., 2016). 
NAFLD is a manifestation of obesity, dyslipidemia, diabetes mellitus, and hypertension 
with a global prevalence rate of 25-30% (Chalasani et al., 2018; Haugen et al., 2018; Marjot et 
al., 2018; Martin et al., 2014; Mikolasevic et al., 2018). NAFLD is described as the presence of 
hepatic steatosis on either imaging or histology without any alternative suspicion for fat 
acquisition such as excessive alcohol consumption or steatogenic medications (Chalasani et al., 
2018; Maurice & Manousou, 2018). NAFLD can be further categorized as non-alcoholic 
steatohepatitis (NASH) or non-alcoholic fatty liver (NAFL). Hepatocellular injury with or 
without the presence of fibrosis is characteristic of NASH whereas NAFL does not involve 
hepatocellular injury and is considered to be a non-aggressive disease process (Chalasani et al., 
2018; Mikolasevic et al., 2018; Pan & Fallon, 2014). NASH can progress to advanced fibrosis or 
cirrhosis and significantly increase the risk for the development of hepatocellular carcinoma 
(Chalasani et al., 2018; Mikolasevic et al., 2018; Perumpail et al., 2017; Pisano et al., 2016).  
NAFLD is predicted to become the leading etiology for liver transplantation in the near 
future and is strongly associated with cardiovascular disease (Chalasani et al., 2018; Haugen et 
al., 2018; Marjot et al., 2018). Liver transplant recipients with a NAFLD etiology have been 
noted to have higher rates of NAFLD recurrence following transplant (Barnard et al., 2016; 
Chalasani et al., 2018; Jimenez-Perez et al., 2016). Alarmingly, up to 40% of liver transplant 
recipients without a NAFLD etiology have been shown to develop NAFLD following transplant 
as well (Jimenez-Perez et al., 2016). Figure 1 highlights additional factors that increase the risk 
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of recurrent or new-onset NAFLD following transplant. Unfortunately, there are no definitive 
pharmacological therapies currently approved for the treatment of NAFLD (Hadi, Vettor, & 
Rosatto, 2018; Maurice & Manousou, 2018). Thus, early identification and appropriate 
management of modifiable risk factors such as obesity, dyslipidemia, diabetes mellitus, and 
hypertension are important in reducing new-onset or recurrent NAFLD following transplant 
(Barnard et al., 2016; Brunault et al., 2015; Jimenez-Perez et al., 2016).  
 
FIGURE 1. Additional risk factors influencing NAFLD. ISD = immunosuppression drugs. 
Practice Guidelines for Metabolic Complications and NAFLD 
Hypertension 
Hypertension strongly correlates with the development of cardiovascular disease related 
events; thus, optimizing control is of vital importance in regard to long-term survival among 
liver transplant recipients (Barnard et al., 2016; Lucey et al., 2013; Whelton et al., 2017). Prior to 
transplant, the incidence of hypertension is low due to the high cardiac output as well as low 
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systemic vascular resistance and mean arterial pressure demonstrated in advanced liver disease 
or cirrhosis (Barnard et al., 2016; Jimenez-Perez et al., 2016). Liver transplantation quickly 
reverses this process with an estimated 40-85% of liver transplant recipients developing 
hypertension and 50% developing the condition within six months of surgery (Barnard et al., 
2016; Jimenez-Perez et al., 2016). The hemodynamic changes as well as immunosuppression 
medications initiated at the time of transplant adversely influence the blood pressure of liver 
transplant recipients (Barnard et al., 2016; Jimenez-Perez et al., 2016; Lucey et al., 2013). 
A target blood pressure of less than 130/80 mmHg is recommended for liver transplant 
recipients given their high risk of developing hypertension and associated cardiovascular events 
following transplant (Barnard et al., 2016; Jimenez-Perez et al., 2016; Lucey et al., 2013; 
Whelton et al., 2017). This target is also in concordance with the latest guidelines published by 
the American College of Cardiology and the American Heart Association. A systolic blood 
pressure greater than 130 mmHg or a diastolic blood pressure greater than 80 mmHg is classified 
as stage I hypertension and warrants lifestyle modifications and/or pharmacological therapies 
(Whelton et al., 2017). Lifestyle modifications include weight loss via healthy dieting and 
increased physical activity, smoking and alcohol cessation, and adherence to a low sodium diet 
(Barnard et al., 2016; Whelton et al., 2017). If lifestyle modifications are not effective in 
lowering blood pressure, then prescription medications are recommended to optimize control 
(Barnard et al., 2016; Jimenez-Perez et al., 2016; Lucey et al., 2013; Whelton et al., 2017).  
Calcium channel blockers are the preferred anti-hypertensive medication for liver 
transplant recipients as they counteract vasoconstriction induced by immunosuppression 
medications such as calcineurin inhibitors (Barnard et al., 2016; Jimenez-Perez et al., 2016; 
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Lucey et al., 2013). Angiotensin-converting enzyme inhibitors or angiotensin receptor blockers 
are recommended for liver transplant recipients with uncontrolled hypertension as well as 
diabetes mellitus, proteinuria, and/or chronic kidney disease (Barnard et al., 2016; Lucey et al., 
2013). However, these medications are felt to more beneficial when initiated in the late post-
transplant period as low plasmin renin activity is demonstrated in the early post-transplant period 
(Barnard et al., 2016). If lifestyle modifications and pharmacological therapies are not successful 
at reducing blood pressure, then a quick steroid taper and/or lowering the dose of or changing 
immunosuppression medication is recommended as deemed appropriate (Barnard et al., 2016). 
Dyslipidemia 
Dyslipidemia like hypertension is uncommon prior to transplant due to the impaired 
hepatic function noted in advanced liver disease or cirrhosis (Barnard et al., 2016; Jimenez-Perez 
et al., 2016; Lucey et al., 2013). A high serum concentration of low-density lipoprotein (LDL) 
cholesterol is indicative of dyslipidemia and strongly associated with increased cardiovascular 
disease risk (Agarwal & Prasad, 2016; Grundy et al., 2018; Husing et al., 2016). Alarmingly, up 
to 71% of liver transplant recipients have been shown to develop dyslipidemia felt to be heavily 
influenced by the adverse cardiovascular effects of immunosuppression medications (Lucey et 
al., 2013). Additional risk factors for the development of dyslipidemia include impaired renal 
function, advanced age, increased body weight, hyperglycemia, and a family history of 
dyslipidemia (Barnard et al., 2016; Husing et al., 2016).  
A target LDL of less than 130 mg/dL has been the standard recommendation for liver 
transplant recipients without additional risk factors (Agarwal & Prasad, 2016; Barnard et al., 
2016; Husing et al., 2016; Jimenez-Perez et al., 2016). The latest guidelines by the American 
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College of Cardiology and the American Heart Association recommend a more aggressive 
approach to reducing cardiovascular disease risk by lowering the LDL to less than 100 mg/dL or 
even further to less than 70 mg/dL depending on the patient’s risk for developing atherosclerotic 
cardiovascular disease events (Grundy et al., 2018). Initiation of a statin is recommended if 
improvement in LDL is unsuccessful with lifestyle modifications alone (Barnard et al., 2016; 
Jimenez-Perez et al., 2016; Grundy et al., 2018; Lucey et al., 2013). Pravastatin is highly 
recommended for liver transplant recipients with dyslipidemia as the medication does not 
become metabolized by the P450 cytochrome or interact with immunosuppression medications 
(Agarwal & Prasad, 2016; Barnard et al., 2016; Husing et al., 2016; Jimenez-Perez et al., 2016). 
Careful review of immunosuppression medications is of significant importance to determine if a 
change in medication would improve the LDL level (Barnard et al., 2016). Current use of 
corticosteroid therapy should also be reviewed and tapered as this medication increases 
cholesterol levels via acetyl coenzyme A carboxylase activity as well as the synthesis of fatty 
acids (Barnard et al., 2016; Jimenez-Perez et al., 2016).  
Obesity 
Obesity is now a national epidemic with a prevalence of nearly 40% affecting over 90 
million people across the country (Centers for Disease Control and Prevention [CDC], 2018a). 
Furthermore, the latest obesity prevalence maps show all states to have over 20% of adults with 
obesity and seven states to have over 35% of adults with obesity (CDC, 2018b). The World 
Health Organization (WHO) (2019) defines obesity as a body mass index (BMI), a calculation 
that takes into account height and weight, of equal to or greater than 30 kg/m2 to be consistent 
with obesity. Risk factors for obesity include dyslipidemia, hypertension, diabetes mellitus, 
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advanced age, and a family history of obesity (Barnard et al., 2016; Chalasani et al., 2018; 
Jimenez-Perez et al., 2016; Pan & Fallon, 2014). Obesity is highly prevalent among liver 
transplant recipients as well and associated with an increased risk of cardiovascular disease 
related events (Table 1).  
Up to 30% of liver transplant recipients are noted to be obese prior to undergoing 
transplant (Barnard et al., 2016). The majority of these patients remain obese following 
transplant, and one-third of recipients who were previously at a normal weight develop obesity 
following transplant as well (Barnard et al., 2016). The aforementioned risk factors for obesity as 
well as corticosteroids initiated at the time of and following transplant play an essential role in 
weight gain (Barnard et al., 2016; Brunault et al., 2015; Jimenez-Perez et al., 2016). Thus, a 
rapid steroid taper is recommended to assist with weight loss. Lifestyle modifications including 
healthy dieting and increased physical activity are encouraged prior to and following transplant 
to reduce the risk of post-operative complications including the development of diabetes mellitus 
and NAFLD (Ayloo, Armstrong, Hurton, & Molinari, 2015; Barnard et al., 2016; Chalasani et 
al., 2018; Jimenez-Perez et al., 2016; Ratziu & Marchesini, 2016).  
Diabetes Mellitus 
According to the American Diabetes Association (ADA) (2018), 1.5 million people in the 
United States (US) are diagnosed with diabetes annually with the cost for diabetes health care 
estimated to be over 300 billion dollars. Diabetes mellitus is associated with poor outcomes 
following transplant as it significantly increases the risk for infection, acute rejection, renal 
dysfunction, cardiovascular disease related events, and overall mortality (Barnard et al., 2016; 
Einarson, Acs, Ludwig, & Panton, 2018; Jimenez-Perez et al., 2016). Diabetes mellitus is 
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estimated to be prevalent in nearly 40% of liver transplant recipients with a new-onset diabetes 
prevalence as high as 30% within the first year of transplant (Barnard et al., 2016). Factors 
influencing the development of diabetes mellitus following transplant include diabetes prior to 
surgery, metabolic syndrome, immunosuppression medications, advanced age, family history of 
insulin resistance, and recurrent hepatitis C or NAFLD (Barnard et al., 2016; Jimenez-Perez et 
al., 2016). Hepatitis C, NAFLD, and alcohol cause significant beta cell damage; thus, 90% of 
patients with advanced liver disease or cirrhosis develop glucose intolerance with 30% 
developing diabetes mellitus (Barnard et al., 2016).  
A hemoglobin (Hgb) A1C target of less than 7% achieved through lifestyle modifications 
and/or pharmacological therapies is recommended following transplant (Barnard et al., 2016; 
Jimenez-Perez et al., 2016; Lucey et al., 2013). The latest guidelines by the American 
Association for the Study of Liver Diseases and the American Society of Transplantation 
recommend monitoring a HgbA1C level every three months following transplant (Lucey et al., 
2013). However, updated management strategies advocate for more frequent monitoring of 
HgbA1C levels on a weekly basis for the first month and then at three, six, and 12 months 
following transplant due to the high risk of development of diabetes mellitus and associated 
cardiovascular disease related mortality among this population (Barnard et al., 2016). Thus, strict 
control via a corticosteroid taper, insulin use, and/or oral diabetic medications in liver transplant 
recipients with normal allograft function is recommended (Barnard et al., 2016; Jimenez-Perez et 
al., 2016). Lastly, careful consideration should be given to altering immunosuppression 
medication as calcineurin inhibitors, particularly Prograf, are associated with increased insulin 
resistance (Barnard et al., 2016; Jimenez-Perez et al., 2016; Lucey et al., 2013).  
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NAFLD 
The rates of NAFLD are rising with increasing rates of obesity and diabetes mellitus 
(Chalasani et al., 2018). A liver biopsy continues to remain the gold standard for the diagnosis of 
NAFLD and staging of fibrosis (Chalasani et al., 2018; Gunn & Shiffman, 2018; Maurice & 
Manousou, 2018). However, a liver biopsy is an invasive procedure with associated serious risks 
such as infection, biopsy site pain, and hemorrhage and is not always feasible due to cost (Pan & 
Fallon, 2014; Wang et al., 2016). Non-invasive measurements of fibrosis and steatosis such as 
the FibroSure serum test, FibroScan, and liver elastography can help identify patients who may 
be at risk for significant disease (Chalasani et al., 2018). Imaging such as a liver ultrasound, 
computed tomography (CT) scan, and magnetic resonance imaging (MRI) can also detect fatty 
infiltration or hepatic steatosis but are unable to differentiate between NAFL and NASH. Thus, a 
liver biopsy is recommended in NAFLD patients with concern for NASH and/or advanced 
fibrosis or to exclude alternative etiologies for hepatic steatosis (Chalasani et al., 2018; 
Lindenmeyer & McCullough, 2017).  
The medical management guidelines for NAFLD following liver transplantation reflect 
those for NAFLD prior to transplant (Chalasani et al., 2018). Optimizing control of hypertension, 
dyslipidemia, diabetes mellitus, and obesity are essential in the medical management of NAFLD 
(Barnard et al., 2016; Chalasani et al., 2018; Maurice & Manousou, 2018). As little as a 5-10% 
reduction in weight via healthy dieting and exercise has been shown to improve NAFLD as well 
as regress fibrosis (Chalasani et al., 2018; Maurice & Manousou, 2018). However, lifestyle 
modifications continue to remain a struggle for many patients and will not be adequate for those 
diagnosed with advanced liver disease or cirrhosis (Maurice & Manousou, 2018). The use of 
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vitamin E in patients with NAFLD has remained controversial as it has been associated with an 
increased risk of hemorrhagic stroke as well as prostate cancer and is not recommended in 
patients with diabetes or advanced liver disease (Hadi et al., 2018). Thus, there are currently no 
pharmacological therapies approved for the successful treatment of NAFLD although numerous 
studies are underway and significant pharmacological advances within the NAFLD realm are 
expected in the near future (Hadi et al., 2018; Lindenmeyer & McCullough, 2017; Maurice & 
Manousou, 2018).  
Additional Risk Factors 
Age, Gender and Ethnicity 
Age, gender, and ethnicity have been shown to be significant risk factors for NAFLD 
(Chalasani et al., 2018; Pan & Fallon, 2014). The risk of NAFLD is felt to increase with age and 
is twice as prevalent in men versus women despite some conflicting research (Ballestri et al., 
2017; Chalasani et al., 2018; Pan & Fallon, 2014). In addition, the Hispanic population has been 
found to be at a greater risk of developing NAFLD with more aggressive disease progression 
(Chalasani et al., 2018; Pan & Fallon, 2014). Both ethnic and gender differences among patients 
diagnosed with NAFLD are suspected to be related to a combination of environmental, genetic, 
and behavioral elements (Bertot & Adams, 2016; Chalasani et al., 2018; Pan & Fallon, 2014). 
Thus, age, gender, and ethnicity are additional factors that should be taken into consideration 
when assessing NAFLD risk prior to and following transplant.
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Immunosuppression Medications 
Liver transplant recipients typically require life-long immunosuppression following 
transplant to prevent rejection and preserve allograft function (Lucey et al., 2013; Song et al., 
2014). Modern advances in immunosuppression medications have helped reduce the risk of 
rejection and associated mortality following transplant (Barnard et al., 2016; Brunault et al., 
2015; Haugen et al., 2018; Martin et al., 2014; Pisano et al., 2016; Song et al., 2014). However, 
immunosuppression medications have been associated with an increased risk of infection, 
malignancy, and adverse cardiovascular profile (Moini, Schilsky, & Tichy, 2015). These 
variables as well as the time since surgery, etiology of liver disease, history of rejection, potential 
for pregnancy, and recipient co-morbidities influence immunosuppression regimen decisions 
(Lucey et al., 2013; Song et al., 2014).  
Common immunosuppression medications include calcineurin inhibitors such as Prograf 
and cyclosporine, a mammalian target of rapamycin (mTOR) inhibitor such as Rapamune, 
corticosteroids such as Solu-Medrol and prednisone, and an anti-proliferative agent such as 
Cellcept (Barnard et al., 2016; Jimenez-Perez et al., 2016; Lucey et al., 2013; Moini et al., 2015; 
Song et al., 2014). Simulect is an immunosuppressive medication used as induction therapy in 
the immediate post-operative period along with intravenous Solu-Medrol to help prevent acute 
cellular rejection episodes. High doses of Solu-Medrol are tapered daily for the first week 
following transplant with transition to an oral prednisone taper. In addition, a calcineurin 
inhibitor and/or an anti-proliferative agent are typically initiated in the early post-transplant 
period and continued indefinitely thereafter as maintenance immunosuppression therapy (Moini 
et al., 2015).  
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Prograf is the preferred calcineurin inhibitor for maintenance immunosuppression therapy 
following transplant due to increased allograft survival and development of fewer acute cellular 
rejection episodes when compared with cyclosporine (Barnard et al., 2016; Moini et al., 2015). 
Furthermore, Prograf is associated with less adverse cardiovascular disease related complications 
and outcomes (Barnard et al., 2016; Fussner et al., 2015; Jimenez-Perez et al., 2016; Moini et al., 
2015).  
Calcineurin inhibitors induce vasoconstriction and steroids increase vascular resistance as 
well as cardiac contractility leading to worsening hypertension or new-onset hypertension 
following transplant (Barnard et al., 2016; Jimenez-Perez, 2016). However, hypertension is noted 
to be more prominent in cyclosporine compared with Prograf (Barnard et al., 2016; Jimenez-
Perez, 2016). Cyclosporine, as well as Rapamune, can increase the risk of dyslipidemia by 
elevating serum lipid concentrations. Thus, Prograf-based immunosuppression is preferred 
unless liver transplant recipients develop significant renal dysfunction warranting a change to 
Rapamune therapy of which close monitoring of lipid levels is highly recommended (Barnard et 
al., 2016).  
Calcineurin inhibitors and corticosteroids also inhibit insulin secretion leading to a 
greater risk of developing diabetes mellitus (Chalasani et al., 2018; Jimenez-Perez et al., 2016). 
Corticosteroids should be tapered quickly to improve hyperglycemia and hypertension as well as 
reduce weight gain often associated with the medication (Barnard et al., 2016; Chalasani et al., 
2018). Careful review of immunosuppression medications as well as the cardiovascular profile of 
each liver transplant recipient is critical as regimens without calcineurin inhibitors or inadequate 
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doses of immunosuppression medications can significantly increase the risk for acute cellular 
rejection (Barnard et al., 2016).  
Local Problem 
A local transplant program in San Antonio, Texas, transplants patients with a variety of 
liver disease including NAFLD and is recognized as one of the top liver transplant programs in 
Texas due to its successful outcomes following liver transplantation (Methodist Physicians San 
Antonio, 2019). Liver transplant program-specific statistics across the country can be located via 
the Scientific Registry of Transplant Recipients. The website provides information regarding the 
number of listed candidates, outcomes while awaiting liver transplantation, details of the 
transplant recipients and donors, wait times on the list, and patient outcomes in regard to survival 
rates following surgery (Scientific Registry of Transplant Recipients, 2019). Unfortunately, 
program-specific data on the prevalence of metabolic complications as well as NAFLD 
following transplant is not readily available despite the increased cardiovascular disease risk 
among this population.  
The local transplant program in San Antonio transplants patients with liver disease from 
all over Texas, which is now listed among the states with more than 30% of adults classified as 
obese (CDC, 2018). San Antonio is a major city located in south-central Texas and has continued 
to struggle with efforts to tackle metabolic complications, particularly obesity and diabetes 
mellitus, as an estimated 71% of adults have been classified as overweight or obese with one out 
of every eight (1:8) residents diagnosed with diabetes mellitus (City of San Antonio 
Metropolitan Health District, 2017). Furthermore, the city comprises of a predominantly 
Hispanic ethnicity (64%), which is a population that has been shown to be at an increased risk of 
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developing NAFLD with more aggressive disease progression (Data USA, 2017; Pan & Fallon, 
2014). Thus, exploring the prevalence of metabolic complications and NAFLD following 
transplant in a community with significant risk factors for the development of cardiovascular 
disease is essential for the implementation of future strategies to reduce cardiovascular disease 
related mortality among liver transplant recipients. 
Study Purpose 
The purpose of this study is to investigate the prevalence of metabolic complications 
among liver transplant recipients at a local transplant program in San Antonio, Texas. Metabolic 
complications are prevalent following liver transplantation and associated with the development 
of recurrent or new-onset NAFLD as well as increased cardiovascular disease risk. Thus, the 
study will assess the prevalence of metabolic complications and NAFLD among the liver 
transplant recipients transplanted between July 2016 and June 2017, which is in concordance 
with the timeframes established by the Scientific Registry of Transplant Recipients. The data 
collected from this study will serve as a foundation for future improvement strategies to reduce 
the prevalence of metabolic complications as well as NAFLD following transplant in an effort to 
also reduce cardiovascular disease risk and improve the quantity and quality of life among liver 
transplant recipients. 
METHODS 
Study Design 
This study involved a retrospective health record review of cardiovascular disease risk in 
patients with liver disease who underwent orthotopic liver transplantation performed by a local 
transplant program in San Antonio, Texas. The data collected were utilized to profile the 
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prevalence of metabolic complications as well as new-onset or recurrent NAFLD among liver 
transplant recipients transplanted between July 2016 and June 2017. 
Sample and Setting 
All adult patients age 18 or older with liver disease who underwent deceased donor liver 
transplantation at the local transplant program between July 1, 2016 and June 30, 2017 were 
included in this study. A total of 47 transplants occurred within this timeframe. Patients who 
underwent a combined liver-kidney transplantation (total of six patients) were excluded to 
provide a more accurate representation of the prevalence of metabolic complications and 
NAFLD among liver only transplant recipients. Thus, 41 charts were reviewed up to one-year 
post-transplant. None of the patients were excluded based on ethnicity or gender. Patients who 
did not survive one-year following surgery were also included and their cause of death listed.  
Data Collection and Use 
Data collection for this DNP study began upon approval by the local (Methodist 
Healthcare System) transplant program’s Institutional Review Board (IRB) as well as the 
University of Arizona IRB (Appendix B & C). A data collection instrument was created based on 
the most updated practice guidelines and management strategies to profile cardiovascular disease 
risk among liver transplant recipients (Appendix A). Metabolic complications, such as 
hypertension, dyslipidemia, diabetes mellitus, and obesity, associated with an increased risk of 
cardiovascular disease as well as new-onset or recurrent NAFLD, were reviewed. Additional 
variables such as etiology of liver disease, ethnicity, age, gender, family history, and 
immunosuppression medications were included. All variables were obtained via retrospective 
review of health care records. The content validity of the data collection instrument was 
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supported by two doctorally prepared advanced practice nurses with expertise in cardiovascular 
and critical care. Data collection was completed at the local transplant program via review of 
electronic medical records. Meditech, Filebound, Velos, and Teleresults were the electronic 
programs accessed to review health care records of liver transplant recipients transplanted 
between July 1, 2016 and June 30, 2017. Study data were managed by the principal investigator 
and recorded electronically on an encrypted work computer provided by the local transplant 
program. 
Study Risks 
This study did not involve greater than minimal risk. Potential risks included breach of 
confidentiality and invasion of privacy. The collection of patients’ private information was 
limited to that of which was necessary to achieve the study purpose as listed in the introduction. 
Electronic safeguards such as passwords, access privileges, encryption, and firewalls were 
implemented to minimize potential risks. Electronic records were only made available to the 
principal investigator, and private information was protected from improper use and disclosure 
via coding practices. The link between the patients’ code and private information was stored on 
the encrypted computer used for data collection and permanently deleted once the study was 
completed. A confidentiality statement agreeing to protect the security of private information 
was signed as well. The collected data was permanently deleted from the encrypted computer per 
hospital protocol once data collection and data analysis were finalized. 
Statistical Analysis 
The International Business Machines (IBM) Statistical Package for the Social Sciences 
(SPSS) version 25 for Mac was utilized to analyze the data collected. Descriptive statistics 
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primarily involving frequency calculations were used to illustrate the prevalence of metabolic 
complications as well as new-onset or recurrent NAFLD among the liver transplant recipients 
selected for data collection. 
RESULTS 
Data Collection 
Data collection occurred between September 26, 2018 and November 6, 2018. The 
medical records of 41 patients who underwent deceased donor liver only transplantation between 
July 1, 2016 and June 30, 2017 were reviewed up to one-year post-transplant. Metabolic 
complications such as hypertension, dyslipidemia, diabetes mellitus, and obesity as well as 
NAFLD were reviewed. Additional variables such as the etiology of liver disease, ethnicity, age, 
gender, family history, and immunosuppression medications were included. The collection of 
BMI, immunosuppression regimen, blood pressure, and prescription medications for co-
morbidities at one-year post-transplant were obtained by review of the clinic visit note. Clinic 
visit dates varied depending on provider and clinic availability; thus, data at the clinic visit 
completed closest to the patient’s one-year post-transplant date were reviewed. Data were 
subsequently entered into the IBM SPSS following collection to complete data analysis.  
Sample Demographic and Survival Characteristics 
Demographic and survival characteristics of the sample are listed in Table 2. The sample 
consisted of 25 (61%) men and 16 (39%) women with 17 (41%) documented as Hispanic and 24 
(59%) documented as non-Hispanic in ethnicity. The mean age of liver transplant recipients was 
55.24 with a standard deviation (SD) of 12.39, ranging from 24 years to 76 years of age. Only 38 
of the 41 (93%) liver transplant recipients were alive at one-year post-transplant. The cause of 
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death for the three (7%) patients who did not survive one-year following transplant included 
septic shock with multi-organ failure, blast crisis with acute respiratory failure, and sudden 
cardiac death. Lastly, one patient did not continue to follow-up in clinic shortly after transplant 
as he moved out of state but continued to complete laboratory testing as directed.  
TABLE 2. Demographic and survival characteristics of patients (N=41). 
Demographic Characteristics 
Age 
 Mean (SD) 55.24 (12.39)  
 Range        24-76 years  
 
  Frequency Percent 
Gender 
 Men 25 61% 
 Women 16 39% 
 
Ethnicity 
 Hispanic 17 41% 
 Non-Hispanic 24 59% 
 
Survival Characteristics 
  Frequency Percent 
Alive at one-year post-transplant 
 Yes 38 93% 
 No 3 7% 
Etiology of Liver Disease 
Etiology of liver disease was identified as NAFLD, other, or unknown (Table 3). There 
were five (12%) patients listed as having NAFLD. The diagnosis of NAFLD was confirmed on a 
liver biopsy performed prior to transplant or on explant. One patient with suspected NASH based 
on medical history as well as negative serologies for alternative causes of chronic liver disease 
and no definitive diagnosis noted on explant was marked as NASH etiology. The majority (81%) 
of the patients were noted to have alternative etiologies for liver disease including hepatitis C, 
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hepatitis B, primary biliary cholangitis, primary sclerosing cholangitis, amyloidosis, Alagille 
syndrome, and alcohol. Only three (7%) patients were marked as having an unknown etiology as 
they presented with acute or fulminant hepatic failure of unknown cause without a definitive 
diagnosis on explant.  
TABLE 3. Patients’ etiology of liver disease (N=41). 
  Frequency Percent 
Etiology    
 NAFLD 5 12% 
 Other 33 81% 
 Unknown 3 7% 
Immunosuppression 
The immunosuppression regimen for liver transplant recipients at the local transplant 
program typically includes Simulect induction, intravenous Solu-Medrol taper with transition to 
oral prednisone, and intravenous Cellcept with transition to oral or no Cellcept. Immediate post-
operative immunosuppression decisions are dependent upon history or evidence of active 
infection and development of significant bone marrow suppression or malignancy (Lucey et al., 
2013; Moini et al., 2015). Of importance, prednisone was typically tapered off prior to or shortly 
after hospital discharge and was not included in the immunosuppression regimen at the time of 
transplant. Only one patient was noted to be on daily prednisone at one-year post-transplant. 
Prednisone was re-started by the patients’ primary care provider due to concern for allograft 
dysfunction related to inadequate immunosuppression as the patient was not taking 
immunosuppression medications as directed. The immunosuppression medications recorded at 
the time of hospital discharge and one-year post-transplant included Prograf, Rapamune, and 
Cellcept (Table 4).  
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At the time of hospital discharge, 17 (42%) patients were on Prograf monotherapy, 23 
(56%) patients were on Prograf and Cellcept, and one (2%) patient was on Rapamune and 
Cellcept. No patients were discharged on Rapamune monotherapy. Immunosuppression 
regimens at one-year post-transplant included 27 (71%) patients on Prograf monotherapy and 
two (5%) on Rapamune monotherapy. The number of patients on Prograf and Cellcept was seven 
(18%). Only one (3%) patient was on both Rapamune and Cellcept. Patients on Rapamune 
therapy at one-year post-transplant were noted to have significant renal dysfunction related to 
calcineurin nephrotoxicity or significant adverse reactions including tremors and altered mental 
status felt to be associated with calcineurin inhibitor use prompting a change in medication.  
TABLE 4. Patients’ immunosuppression at time of transplant and one-year post-transplant.  
 Frequency Percent 
 
Immunosuppression at transplant (N=41) 
Prograf 17 42% 
Prograf and Cellcept 23 56% 
Rapamune and Cellcept 1 2% 
 
Immunosuppression at one-year post-transplant (N=38) 
Prograf 27 71% 
Rapamune 2 5% 
Prograf and Cellcept 7 18% 
Rapamune and Cellcept 1 3% 
Other (Prograf and prednisone) 1 3% 
History 
Family History 
The family history of each patient (Table 5) was obtained by review of hospital progress 
notes, outpatient clinic visit reports, history and physicals performed by hospitalists, and 
consultation reports completed by specialists. Notes that did not specify a family history of the 
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metabolic complication or a family history reported as “non-contributory” were regarded as 
unknown as “non-contributory” is generally not accepted as adequate documentation (Hughes, 
2017). All 41 (100%) patients did not have a family history of obesity or dyslipidemia specified 
in the medical records. The majority of the patients, 27 (66%) and 32 (78%), did not have a 
family history of diabetes mellitus or hypertension specified in the medical records, respectively. 
Only 14 (34%) and nine (22%) patients had a recorded family history of type 2 diabetes and 
hypertension, respectively.  
TABLE 5. Patients’ family history of metabolic complications (N=41). 
  Frequency Percent 
Family History 
 Obesity - - 
 No Obesity - - 
 Unknown 41 100% 
 
 Dyslipidemia - - 
 No Dyslipidemia - - 
 Unknown 41 100% 
 
 Type 2 Diabetes 14 34% 
 No Type 2 Diabetes - - 
 Unknown 27 66% 
 
 Hypertension 9 22% 
 No Hypertension - - 
 Unknown 32 78% 
Patient History 
Each patient’s medical history (Table 6) was obtained by review of hospital progress 
notes, outpatient clinic visit reports, history and physicals performed by hospitalists, and 
consultation reports completed by specialists. The BMI of each patient was calculated at the time 
of transplant and used to determine obesity prior to transplant (Table 7). The majority of patients 
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(56%) had a recorded history of hypertension prior to transplant. Only eight (20%) and 10 (24%) 
patients had a recorded history of dyslipidemia and type 2 diabetes prior to transplant, 
respectively.  
TABLE 6. Patients’ history of metabolic complications (N=41). 
  Frequency Percent 
Patient History 
 Dyslipidemia 8 20% 
 No Dyslipidemia 33 80% 
 
 Type 2 Diabetes 10 24% 
 No Type 2 Diabetes 31 76% 
 
 Hypertension 23 56% 
 No Hypertension 18 44% 
Metabolic Complications 
Obesity 
BMI was reviewed at the time of transplant and at the clinic visit closest to one-year post-
transplant (Table 7). The majority of the patients had a BMI of less than 30 kg/m2 prior to (66%) 
and following transplant (59%). BMI at the time of transplant may have been lower than 
expected due to malnutrition often associated with chronic liver disease or cirrhosis (Chaney & 
Heckman, 2018). The number of patients with a BMI of less than 30 kg/m2 decreased at one-year 
post-transplant due to four patients not surviving one-year or lost to follow-up after surgery. A 
total of 12 out of the 14 patients who were obese prior to transplant remained obese at one-year 
post-transplant. However, BMI at the time of surgery may have also been skewed due to the 
presence of ascites (Barnard et al., 2016). Three patients who were not obese prior to surgery 
were noted to have a BMI of greater than or equal to 30 kg/m2 at one-year post-transplant. Only 
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two patients who were obese prior to transplant were able to lose weight to achieve a BMI of less 
than 30 kg/m2 at one-year post-transplant. 
TABLE 7. Patients’ BMI at time of transplant and one-year post-transplant. 
  Frequency Percent 
BMI at transplant (N=41) 
 BMI ≥ 30 (kg/m2) 14 34% 
 BMI < 30 (kg/m2) 27 66% 
 
BMI at one-year post-transplant (N=37) 
 
 BMI ≥ 30 (kg/m2) 15 41% 
 BMI < 30 (kg/m2) 22 59% 
Dyslipidemia 
LDL levels closest to the time of transplant and at one-year post-transplant were reviewed 
(Table 8). The majority of patients (81%) did not have documented LDL levels prior to 
transplant. Eight patients had a recorded LDL level at the time of or prior to transplant with 
seven (17%) noted to have a LDL level of less than 130 mg/dL and only one (2%) noted to have 
a LDL level higher than 130 mg/dL. The patient who had a LDL level greater than 130 mg/dL at 
the time of transplant continued to have a LDL level greater than 130 mg/dL at one-year post-
transplant and was not on statin therapy at either time point. There were six patients (16%) with a 
documented LDL level of less than 130 mg/dL at one-year post-transplant. However, the number 
of unknown LDL levels remained significantly high (82%) at one-year post-transplant and may 
not have accurately reflected the number of patients with abnormal or normal LDL levels. Only 
two patients (one with a history of dyslipidemia) were started on statin therapy with Lipitor 
following surgery and neither had a LDL level documented at one-year post-transplant.  
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TABLE 8. Patients’ LDL at time of transplant and one-year post-transplant. 
  Frequency Percent 
LDL at transplant (N=41) 
 LDL > 130 mg/dL 1 2% 
 LDL < 130 mg/dL 7 17% 
 Unknown 33 81% 
 
LDL at one-year post-transplant (N=38) 
 LDL > 130 mg/dL 1 3% 
 LDL < 130 mg/dL 6 16% 
 Unknown 31 82% 
Note. Percentages may not total 100 due to rounding. 
Diabetes Mellitus 
HgbA1C levels were reviewed at the time of transplant, weekly for the first month 
following transplant, and then at three, six, and 12 months following transplant (Table 9). The 
total number of patients at each time frame accounts for those who did not survive to one-year 
post-transplant and varies depending on time of death. Alarmingly, 56-100% of data were 
marked as unknown as no HgbA1C levels were documented in the available health records at the 
specified time frames despite 24% of patients recorded as having a history of type 2 diabetes 
prior to transplant.  
HgbA1C was noted to be less than 7% among the majority of patients (42%) who had a 
documented level at the time of or prior to transplant. Of the 31 patients without a history of type 
2 diabetes and not on medication prior to transplant, three were started on medication for 
hyperglycemia following surgery and continued on therapy for post-transplant diabetes at one-
year post-transplant. HgbA1C was documented prior to transplant and at three- and six-months 
post-transplant for only one of these three patients. Furthermore, three of the 10 patients with a 
history of type 2 diabetes continued on treatment for diabetes at one-year post-transplant. Only 
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two of these patients had a documented HgbA1C level prior to or at the time of transplant and at 
week four as well as three- and six-months post-transplant. HgbA1C levels at one-year post-
transplant were not documented for any patients who continued on therapy for diabetes at that 
time. Documented medications for the management of diabetes mellitus following transplant 
included pioglitazone, metformin, glimepiride, Tradjenta, Humalog and Lantus.  
TABLE 9. Patients’ HgbA1C at time of transplant, three- and six-months post-transplant, and 
one-year post-transplant. 
  Frequency Percent 
HgbA1C at transplant (N=41) 
 HgbA1C > 7% 1 2% 
 HgbA1C < 7% 17 42% 
 Unknown 23 56% 
 
HgbA1C at one-week post-transplant (N=40) 
 HgbA1C > 7% - - 
 HgbA1C < 7% 1 2% 
 Unknown 39 98% 
 
HgbA1C at two-weeks post-transplant (N=40) 
 HgbA1C > 7% - - 
 HgbA1C < 7% 1 2% 
 Unknown 39 98% 
 
HgbA1C at three-weeks post-transplant (N=40) 
 HgbA1C > 7% - - 
 HgbA1C < 7% - - 
 Unknown 40 100% 
 
HgbA1C at four-weeks post-transplant (N=40) 
 HgbA1C > 7% - - 
 HgbA1C < 7% 1 2% 
 Unknown 39 98% 
 
HgbA1C at three-months post-transplant (N=40) 
 HgbA1C > 7% - - 
 HgbA1C < 7% 4 10% 
 Unknown 36 90% 
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TABLE 9 – Continued  
  Frequency Percent 
 
 
HgbA1C at six-months post-transplant (N=39) 
 HgbA1C > 7% 1 3% 
 HgbA1C < 7% 2 5% 
 Unknown 36 92% 
 
HgbA1C at one-year post-transplant (N=38) 
 HgbA1C > 7% - - 
 HgbA1C < 7% 2 5% 
 Unknown 36 95% 
Hypertension 
Blood pressure was reviewed at the time of transplant and at the clinic visit closest to 
one-year post-transplant (Table 10). Only 12 (29%) of the 41 patients were documented to have a 
blood pressure greater than 130/80 mmHg at the time of transplant. However, a blood pressure of 
greater than 130/80 mmHg was documented in 24 (65%) patients at one-year post-transplant. 
The patients who did not survive one-year post-transplant or follow-up in clinic at one-year post-
transplant were not included in the total at that time. 
Approximately 54% (n=20) of patients were documented to be on anti-hypertensive 
medication at one-year post-transplant. Furthermore, 16 of the 23 patients with a history of 
hypertension prior to transplant and four of the 18 patients without a history of hypertension 
were documented to be on anti-hypertensive medication at one-year post-transplant. Alarmingly, 
14 of the 20 patients on anti-hypertensive therapy were noted to have a blood pressure of greater 
than 130 mmHg systolic and/or 80 mmHg diastolic at their clinic visit closest to one-year post-
transplant. Furthermore, five of the 14 patients with uncontrolled blood pressure had NAFLD 
prior to transplant. Only one patients’ anti-hypertensive medication regimen was altered at the 
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clinic visit. Another patients’ regimen was not changed due to the patient not taking anti-
hypertensive medication the morning of the clinic visit. Further hypertensive management was 
documented as to defer to the primary care provider or specialist. In addition, 10 patients without 
a documented history of hypertension were noted to have a blood pressure of greater than 130 
mmHg systolic and/or 80 mmHg diastolic at one-year post-transplant and were not on or started 
on therapy at that time. Documented anti-hypertensive medications included metoprolol, Coreg, 
lisinopril, losartan, hydrochlorothiazide, amlodipine, nifedipine, and propranolol. 
TABLE 10. Patients’ blood pressure at time of transplant and one-year post-transplant. 
  Frequency Percent 
Blood pressure at transplant (N=41) 
 BP > 130/80 mmHg 12 29% 
 BP < 130/80 mmHg 29 71% 
 
Blood pressure at one-year post-transplant (N=37) 
 BP > 130/80 mmHg 24 65% 
 BP < 130/80 mmHg 13 35% 
NAFLD 
The presence of NAFLD on imaging and liver biopsy was reviewed at the time of 
transplant and closest to one-year post-transplant (Table 11). A liver biopsy is generally 
performed within one week of surgery at the local transplant program in order to evaluate for 
early acute cellular rejection, alternative reasons for allograft dysfunction, or to assist with 
immunosuppression regimen decisions. Further biopsies as well as imaging are based upon 
allograft function and are an individualized decision per the transplant program’s protocol 
(Lucey et al., 2013). Thus, the pathology of the most recent liver biopsy documented within one-
year of transplant was reviewed as liver biopsies are not routinely performed at one-year post-
transplant unless otherwise indicated. Doppler ultrasounds performed immediately following 
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transplant evaluate for potential vascular complications (Sanyal et al., 2014). Thus, Doppler 
ultrasounds were excluded from imaging reviewed for the presence of hepatic steatosis. Patients 
who did not survive to one-year post-transplant or who did not have imaging other than a 
Doppler ultrasound or further liver biopsies performed following transplant were marked as 
Unknown.  
There were no patients with hepatic steatosis on imaging immediately following 
transplant. However, three patients developed fatty infiltration on imaging within one-year post-
transplant. Of concern, one of the patients who developed fatty infiltration on imaging was the 
patient lost to follow-up. Only two patients had mild macrovesicular steatosis noted on liver 
biopsy pathology immediately following transplant. Both patients continued to display evidence 
of macrovesicular steatosis with one of the patients progressing to severe macrovesicular 
steatosis upon liver biopsy pathology closest to one-year post-transplant. Neither patients had 
evidence of steatohepatitis concerning for NASH or fibrosis noted on liver biopsy pathology 
reports. Fatty infiltration or hepatic steatosis was only noted on imaging closest to one-year post-
transplant for the patient with macrovesicular progression. Lastly, two patients developed 
macrovesicular steatosis on liver biopsy closest to one-year post-transplant who did not have 
steatosis noted on liver biopsy or imaging immediately following transplant. Neither of these two 
patients had evidence of steatohepatits concerning for NASH or fibrosis noted on liver biopsy 
pathology.  
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TABLE 11. Patients’ with NAFLD at time of transplant and one-year post-transplant (N=41). 
NAFLD on Imaging Frequency Percent 
At time of transplant 
 Yes 0 0 
 No 24 59% 
 Unknown 17 41% 
 
At one-year post-transplant 
 Yes 3 7% 
 No 26 63% 
 Unknown 12 29% 
 
NAFLD on Liver Biopsy Frequency Percent 
At time of transplant 
 Yes 2 5% 
 No 38 93% 
 Unknown 1 2% 
 
At one-year post-transplant 
 Yes 4 10% 
 No 27 66% 
 Unknown 10 24% 
Note. Percentages may not total 100 due to rounding. 
Cardiovascular Disease Risk 
No cardiovascular disease related events such as myocardial infarction, stroke, peripheral 
vascular disease, or coronary artery disease were documented within the first year of transplant 
among the study sample. Only five (12%) patients were noted to have hepatic steatosis via 
imaging and/or liver biopsy following transplant. Thus, the risk factors for NAFLD as well as 
metabolic complications associated with increased cardiovascular disease risk were explored in 
these five patients. Of these, only one patient was noted to be over the age of 50 and four patients 
were men. Furthermore, two men were of Hispanic ethnicity and one had a liver disease etiology 
of NAFLD. The remaining patients had alternative etiologies for chronic liver disease. All 
patients were on the calcineurin inhibitor, Prograf, at one-year post-transplant. None of the 
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patients had a documented history of dyslipidemia and were not on medication prior to or 
following transplant for dyslipidemia. However, a LDL level following transplant was not 
documented on any of the patients.  
The man over the age of 50 and of Hispanic ethnicity was noted to have a family as well 
as personal history of type 2 diabetes and hypertension requiring medications prior to transplant. 
No medications for hypertension or diabetes mellitus were noted at his clinic visit closest to one-
year post-transplant. Blood pressure was normal at that time; however, a HgbA1C level was not 
documented. The patient was successful in losing 16 pounds of body weight since the time of 
transplant which may have contributed to improved blood pressure and possibly glucose control 
following transplant. Furthermore, liver biopsy pathology showed improvement from mild to 
minimal macrovesicular steatosis.  
The man with a history of NAFLD and obesity prior to transplant was also successful in 
losing weight following transplant. He did not have a documented history of hypertension; 
however, he was noted to have hypertension at the time of and at one-year post-transplant. No 
anti-hypertensive medication was documented following surgery. Furthermore, the patient did 
not have a history of type 2 diabetes but was started on Lantus and Humalog following transplant 
which were ultimately discontinued. He was not on medications for hyperglycemia at his clinic 
visit closest to one-year post-transplant; however, a HgbA1C level was not documented to 
confirm glucose control. Despite weight loss, his liver biopsy pathology closest to one-year post-
transplant showed mild macrovesicular steatosis.  
Another man without a history of dyslipidemia, hypertension, diabetes mellitus, or 
obesity was noted to have minimal to mild macrovesicular and microvesicular steatosis 
 
  
41 
documented on liver biopsy pathology closest to one-year post-transplant. He developed steroid 
induced hyperglycemia following transplant but did not continue on insulin after hospital 
discharge. In addition, he was not on medication for diabetes mellitus, hypertension, or 
dyslipidemia at his clinic visit closest to one-year post-transplant. Blood pressure was normal at 
his clinic visit, and a HgbA1C level was not documented post-transplant. The patient was noted 
to have a significant weight gain of 37 pounds with a BMI of 32 kg/m2 documented at one-year 
post-transplant which may have contributed to the development of post-transplant steatosis. 
The woman with progression from minimal to severe macrovesicular steatosis upon liver 
biopsy pathology did have a history of obesity and hypertension prior to transplant. BMI 
decreased from 36 kg/m2 to 31 kg/m2 and blood pressure was well controlled on an anti-
hypertensive medication at her clinic visit closest to one-year post-transplant. The patient did not 
have a documented history of diabetes mellitus but did require intravenous insulin following 
surgery. She did not continue on insulin therapy following hospital discharge and was not on 
medication at one-year post-transplant; however, a HgbA1C level was not documented to 
confirm glycemic control.  
Lastly, the man of Hispanic ethnicity with fatty infiltration noted on imaging did not 
continue to follow-up in clinic shortly after transplant; however, he did continue to undergo 
laboratory testing to monitor liver function tests and immunosuppression levels. No history of 
obesity, hypertension, or dyslipidemia was documented. However, the patient did require 
intravenous insulin following transplant and was discharged home on Lantus as well as 
Humalog. A HgbA1C level was not documented after transplant. Unfortunately, the patient does 
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not have a BMI, blood pressure, or medications for co-morbidities documented either due to no 
longer following-up in clinic. 
DISCUSSION 
Summary of Findings 
The electronic health care records of 41 transplant recipients who underwent liver only 
transplantation by a local transplant program in San Antonio, Texas, between July 1, 2016 and 
June 30, 2017 were reviewed up to one-year post-transplant. Of the 41 patients, three did not 
survive to one-year post-transplant and one was lost to follow-up with the program but did 
continue to undergo laboratory testing as directed. No cardiovascular disease related events such 
as myocardial infarction, stroke, peripheral vascular disease, or coronary artery disease were 
documented within the first year following transplant. A similar study by Fussner et al. (2015) 
demonstrated cardiovascular disease to be common following transplant with 10.6% of patients 
having developed a cardiovascular event within the first year of surgery. However, analysis on 
the prevalence of hypertension, diabetes mellitus, and hyperlipidemia was not explored as in this 
study (Fussner et al., 2015). 
Studies have shown up to 71% and 30% of transplant recipients to develop dyslipidemia 
and diabetes mellitus within the first year of transplant, respectively (Barnard et al., 2016; Lucey 
et al., 2013). However, the majority of the patients in the present study did not have documented 
LDL or HgbA1C levels which are valuable markers indicative of increased cardiovascular 
disease risk (Agarwal et al., 2016; Barnard et al., 2016; Grundy et al., 2018; Husing et al., 2016). 
In the present study, the majority of the patients who were obese at the time of transplant 
remained obese at one-year post-transplant. Surprisingly, 66% of patients had a BMI of less than 
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30 kg/m2 prior to transplant and 59% had a BMI of less than 30 kg/m2 following transplant. 
Discrepancies in BMI in this study versus estimated prevalence rates may have been due to BMI 
not accounting for malnutrition as well as ascites associated with chronic liver disease or 
cirrhosis (Barnard et al., 2016; Chaney & Heckman, 2018). Thus, BMI at the time of transplant 
may not serve as a reliable measure of obesity prior to transplant. Review of hypertension 
provided the most comprehensive data as a blood pressure was documented at the time of 
transplant and at the clinic visit closest to one-year post-transplant on all patients who survived 
one-year post-transplant and continued to follow-up in clinic. In the present study, approximately 
65% of patients were noted to have hypertension at one-year post-transplant which is in 
congruence with the estimated hypertension prevalence rate of 50% following 6 months of 
surgery (Barnard et al., 2016; Jimenez-Perez et al., 2016).  
NAFLD is a manifestation of metabolic complications found to be common among liver 
transplant recipients (Chalasani et al., 2018; Haugen et al., 2018; Marjot et al., 2018; Martin et 
al., 2014; Mikolasevic et al., 2018; Patel, Berg, & Moylan, 2016). Approximately 30-60% of 
patients transplanted for NASH cirrhosis and 20-40% of patients without a NASH etiology of 
liver disease are estimated to develop NAFLD within a one- to five-year post-transplant period 
(Chalasani et al., 2018; Jimenez-Perez et al., 2016; Pais et al., 2016). A study by Hejlova et al. 
(2016) showed 26% of patients to have steatosis present on liver biopsy at one-year post-
transplant. Thus, recurrent or new-onset NAFLD following transplant was not prevalent in this 
study as only five (12%) patients developed hepatic steatosis on imaging and/or liver biopsy 
following transplant with only one of the patients having a NAFLD etiology prior to transplant. 
None of the patients had evidence of NASH or fibrosis on liver biopsy pathology. Fortunately, 
 
  
44 
development of NAFLD following transplant typically yields a low risk of progression to 
advanced liver disease or re-current cirrhosis (Martin et al., 2014; Patel et al., 2016).  
Additional risk factors such as male gender, Hispanic ethnicity, advanced age, and 
immunosuppression medications for the development of NAFLD and associated cardiovascular 
disease risk were explored with particular focus on the patients who developed NAFLD 
following transplant. All subjects were on the calcineurin inhibitor, Prograf, which is the 
preferred immunosuppression medication following transplant as it has been shown to increase 
allograft survival and demonstrate a less adverse cardiovascular profile (Barnard et al., 2016; 
Fussner et al., 2015; Jimenez-Perez et al., 2016; Moini et al., 2015). Of the five patients with 
hepatic steatosis on imaging and/or liver biopsy following transplant, 80% were of male gender 
which is consistent with studies showing NAFLD to be twice as prevalent in men versus women 
(Ballestri et al., 2017; Chalasani et al., 2018; Pan & Fallon, 2014). Only 40% of the patients with 
hepatic steatosis following transplant were of Hispanic ethnicity, and only one patient was noted 
to be over the age of 50. Thus, advanced age and Hispanic ethnicity in the present study did not 
correlate with an increased risk for developing NAFLD following transplant. 
In summary, this study showed hypertension to be the most frequently documented 
metabolic complication that was prevalent among liver transplant recipients at one-year post-
transplant and sub-optimally managed. The study failed to truly capture the prevalence of other 
metabolic complications and associated cardiovascular disease risk among the study population 
due to missing data, particularly in regard to LDL and HgbA1C levels. The prevalence of 
recurrent or new-onset NAFLD was low in this study and may be better captured in the late post-
transplant period. Patients who developed hepatic steatosis following transplant did not have 
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evidence of NASH or fibrosis on liver biopsy pathology. The study sample consisted of a 
predominantly male population; however, the mean age was only 55 and patients were primarily 
of non-Hispanic ethnicity which were not considered risk factors for the development of 
NAFLD. Lastly, no cardiovascular disease related events were documented within the first year 
following transplant.  
Limitations and Strengths 
The study sample size was relatively small as the number of transplants during the July 
2016 through June 2017 timeframe was lower than the 70 transplants performed by the local 
transplant program the prior year (Scientific Registry of Transplant Recipients, 2018). Only 41% 
of the patients were of Hispanic ethnicity which does not reflect the predominantly Hispanic 
community of San Antonio. In addition, only 12% of the patients in this study had a documented 
NAFLD etiology of liver disease prior to transplant. The low prevalence of Hispanic ethnicity 
and NAFLD may have been attributed to the transplant program performing transplants on 
patients from outside of San Antonio as well. Furthermore, there are two transplant programs 
located in San Antonio; thus, a future study encompassing data from both programs may better 
reflect the Hispanic community of San Antonio as well as the number of transplant recipients 
transplanted for NAFLD. 
In the present study, patients’ records were only reviewed up to one-year post-transplant. 
A long-term evaluation post-transplant may provide a more accurate depiction of metabolic 
complications and associated cardiovascular disease related mortality among the liver transplant 
recipients transplanted at this transplant program. Furthermore, the retrospective design of this 
study relied on available data documented within hospital progress notes, outpatient clinic visit 
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reports, history and physicals by hospitalists, and consultation reports by specialists to provide 
the patients’ medical history and diagnoses as well as management strategies for post-transplant 
metabolic complications. Follow-up clinic visit dates at one-year post-transplant varied 
depending on clinic and provider availability which may have not accurately captured the 
prevalence of metabolic complications as well as recurrent or new-onset NAFLD within one-
year of transplant. In addition, only laboratory testing performed at the local transplant program 
or via commercial laboratory testing centers ordered by the Hepatology and Transplant provider 
and scanned into the electronic medical record were available for review. Thus, HgbA1C and 
LDL levels performed through primary care providers or specialists as an outpatient may not 
have been accounted for if results were not requested or brought to the clinic by the patient. 
Missing data may have skewed the study outcomes and significantly underestimated the 
prevalence of metabolic complications and associated cardiovascular disease risk among liver 
transplant recipients at this transplant program. 
In regard to study strengths, this is the first study to the author’s knowledge that 
investigates the prevalence of metabolic complications as well as NAFLD and associated 
cardiovascular disease risk among liver transplant recipients at this transplant program in San 
Antonio, Texas. Furthermore, this study is one of few throughout the literature that investigates 
multiple research variables among liver transplant recipients including the prevalence of 
hypertension, diabetes mellitus, dyslipidemia, and obesity; additional risk factors such as age, 
ethnicity, gender, etiology of liver disease, family history, and immunosuppression medications; 
the prevalence of recurrent and new-onset NAFLD; and cardiovascular disease risk following 
transplant.  
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Implications for Advanced Practice Nursing 
The prevention and adequate management of metabolic complications is crucial in 
reducing cardiovascular disease related events and increasing longevity among liver transplant 
recipients (Barnard et al., 2016). Although immunosuppression medications have helped lower 
the risk for acute cellular rejection and increase related survival, they are associated with the 
development of an adverse cardiovascular profile (Barnard et al., 2016; Brunault et al., 2015; 
Haugen et al., 2018; Martin et al., 2014; Moini et al., 2015; Pisano et al., 2016; Song et al., 
2014). Age, ethnicity, and gender have also been shown to increase the risk for NAFLD and 
associated cardiovascular disease risk following transplant (Chalasani et al., 2018; Pan & Fallon, 
2014). Thus, understanding the risk factors for metabolic complications, NAFLD, and 
cardiovascular disease as well as implementing appropriate practice guidelines and management 
strategies following transplant may help improve outcomes among liver transplant recipients.  
Communication between Hepatology specialists and primary care providers is vital for 
the early recognition and appropriate management of post-transplant metabolic complications 
(Barnard et al., 2016). Coordination with a dietician and physical therapist may help promote 
lifestyle modifications via patient education as healthy dieting and increased physical activity 
have been shown to prevent and improve metabolic complications as well as NAFLD (Barnard et 
al., 2016; Chalasani et al., 2018; Maurice & Manousou, 2018; Patel et al., 2016). 
Immunosuppression decisions in collaboration with a pharmacist may also prove beneficial in 
reducing cardiovascular disease risk factors while maintaining adequate immunosuppression 
levels to prevent acute cellular rejection (Barnard et al., 2016). Thus, a multi-disciplinary 
approach is imperative to the successful implementation of the aforementioned strategies in an 
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effort to reduce the prevalence of metabolic complications as well as NAFLD and associated 
cardiovascular disease risk among liver transplant recipients.  
Lastly, improved documentation is necessary to more accurately capture the prevalence 
of metabolic complications and associated cardiovascular disease risk among liver transplant 
recipients. Records of pertinent laboratory values and/or imaging should be requested and 
appropriately documented if testing is performed outside of the transplant program. Prospective 
studies are needed to further evaluate the prevalence of metabolic complications and associated 
cardiovascular disease risk among this population due to the missing data in this study.  
Conclusions 
Survival rates among liver transplant recipients have significantly improved particularly 
with modern advances in surgical techniques and immunosuppression medications (Barnard et 
al., 2016; Brunault et al., 2015; Haugen et al., 2018; Martin et al., 2014; Pisano et al., 2016; Song 
et al., 2014). However, metabolic complications such as hypertension, obesity, dyslipidemia, and 
diabetes mellitus as well as recurrent or new-onset NAFLD have become exceedingly prevalent 
following transplant and are associated with increased cardiovascular disease risk and related 
mortality (Barnard et al., 2016; Brunault et al., 2015; Fussner et al., 2015; Glowczynska et al., 
2018; Jimenez-Perez et al., 2016; Marjot et al., 2018; Pisano et al., 2016; Wang et al., 2016). 
Additional factors influencing the development of NAFLD and associated cardiovascular disease 
risk include advanced age, male gender, Hispanic ethnicity, and immunosuppression medications 
initiated following transplant (Chalasani et al., 2018; Moini et al., 2015; Pan & Fallon, 2014). 
Thus, optimal management of modifiable risk factors is necessary to reduce cardiovascular 
disease risk. 
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Retrospective health care record review employed in this DNP study was an insufficient 
method for profiling cardiovascular disease risk due to missing data and, thus, inadequate to truly 
capture the prevalence of metabolic complications as well as NAFLD and associated 
cardiovascular disease risk among liver transplant recipients. Appropriate documentation of 
HgbA1C and LDL levels may prove beneficial in the assessment of post-transplant patients at 
risk for cardiovascular disease. Furthermore, better control of blood pressure may help reduce 
cardiovascular disease risk in the late post-transplant period. Findings from this DNP study serve 
as the foundation for future prospective studies to further investigate the prevalence of metabolic 
complications following transplant in an effort to prevent the development and optimize the 
medical management of hypertension, diabetes mellitus, dyslipidemia, and obesity as well as 
NAFLD and reduce associated cardiovascular disease risk among liver transplant recipients. 
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APPENDIX A: 
DATA COLLECTION INSTRUMENT 
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CARDIOVASCULAR PROFILE OF LIVER TRANSPLANT RECIPIENTS 
Data collection date (mm/dd/yy): _________ 
Patient’s code number: ______ 
Transplant date (mm/dd/yy): ______ 
Age at date of transplant: ______ 
Etiology of liver disease: 
NAFLD/Other/Unknown 
Patient alive at 1-year post-transplant: 
Yes/No  
Ethnicity 
Hispanic/Non-Hispanic/Unknown  
Gender: 
Male/Female 
Immunosuppression:  
At time of transplant:  
Prograf/Rapamue/Cyclosporine/Cellcept/Other ______ 
 
At 1-year post-transplant:  
Prograf/Rapamue/Cyclosporine/Cellcept/Other ______ 
 
 
Height and Weight: 
 
At time of transplant – Date: _____  
Height: ______ (in) or ______ (cm)  
Weight: ______ (lbs) or ______ (kg) 
BMI: ______ (kg/m2) 
 
 BMI: > or = to 30 kg/m2 
Yes/No/Unknown  
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At 1-year post-transplant – Date: _____ 
Height: ______ (in) or ______ (cm)  
Weight: ______ (lbs) or ______ (kg) 
BMI: ______ (kg/m2) 
  
BMI: > or = to 30 kg/m2 
Yes/No/Unknown  
 
Family history of obesity:  
Yes/No/Unknown 
 
Dyslipidemia: 
Patient history of dyslipidemia:  
Yes/No/Unknown 
 
Family history of dyslipidemia:  
Yes/No/Unknown 
 
Fasting lipid panel closest to date of transplant – Date: _____ 
Low-density lipoprotein cholesterol: ______ mg/dL 
 
LDL > 130 mg/dL 
Yes/No/Unknown  
 
On a lipid-lowering medication: 
Yes/No/Unknown 
If yes, specify name and dose: __________ 
 
Fasting lipid panel at 1-year post-transplant – Date: _____ 
Low-density lipoprotein cholesterol: ______ mg/dL 
 
LDL > 130 mg/dL 
Yes/No/Unknown 
 
On a lipid-lowering medication: 
Yes/No/Unknown 
If yes, specify name and dose: _________ 
 
Diabetes Mellitus:  
 
Patient history of diabetes:  
  Yes/No/Unknown 
 
Family history of diabetes:  
  Yes/No/Unknown 
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HgbA1C closest to date of transplant – Date: ______ 
HgbA1C at week 1 post-transplant: ______ 
  HgbA1C > 7% 
Yes/No/Unknown 
 
HgbA1C at week 2 post-transplant: ______ 
  HgbA1C > 7% 
Yes/No/Unknown 
 
HgbA1C at week 3 post-transplant: ______ 
  HgbA1C > 7% 
Yes/No/Unknown 
 
HgbA1C at week 4 post-transplant: ______ 
  HgbA1C > 7% 
Yes/No/Unknown 
 
  HgbA1C at 3 months post-transplant: ______ 
  HgbA1C > 7% 
Yes/No/Unknown 
 
HgbA1C at 6 months post-transplant: ______ 
  HgbA1C > 7% 
Yes/No/Unknown 
 
On a glycemic control medication at time of transplant: 
Yes/No/Unknown 
If yes, specify name and dose: __________ 
 
HgbA1C at 1-year post-transplant – Date: ______ 
HgbA1C > 7% 
Yes/No/Unknown 
 
On a glycemic control medication: 
Yes/No/Unknown 
If yes, specify name and dose: __________ 
 
 Hypertension: 
 
Patient history of hypertension:  
  Yes/No/Unknown 
 
Family history of hypertension:  
  Yes/No/Unknown 
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At time of transplant – Date: ______ 
Systolic blood pressure: ______mmHg 
Diastolic blood pressure: ______mmHg  
 
BP >130/80 mmHg 
Yes/No/Unknown 
 
On an antihypertensive medication: 
Yes/No/Unknown 
If yes, specify name and dose: __________ 
 
At 1-year post-transplant – Date: ______ 
Systolic blood pressure: ______mmHg 
Diastolic blood pressure: ______mmHg  
 
BP >130/80 mmHg 
Yes/No/Unknown 
  
On an antihypertensive medication: 
Yes/No/Unknown 
If yes, specify name and dose: __________ 
 
NAFLD: 
 
Liver biopsy at time of transplant – Date: ______  
Evidence of NAFLD Yes/No/Unknown 
 
Liver biopsy closest to 1-year post-transplant – Date: ______ 
Evidence of NAFLD Yes/No/Unknown 
 
Imaging (CT/MRI/US) at time of transplant – Date: ______  
Evidence of NAFLD Yes/No/Unknown 
 
Imaging (CT/MRI/US) closest to 1-year post-transplant – Date: ______  
Evidence of NAFLD Yes/No/Unknown 
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APPENDIX B: 
METHODIST HEALTHCARE SYSTEM INSTITUTIONAL REVIEW BOARD (IRB) 
APPROVAL LETTER 
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- 1 - Generated on IRBNet
  
INSTITUTIONAL REVIEW BOARD
FWA00000435
8109 Fredericksburg Road, 3rd Floor, San Antonio, TX 78229
Telephone: (210) 575-4918
Fax: (210) 575-0587
MHS IRB web site: https://sites.google.com/site/mhsirbsatx/
 
 
August 10, 2018
 
Katrina Peterson, MSN
6974 Oak Drive Apt. 1201
San Antonio, TX   78256
 
Re: [1289067-1] Metabolic Complications and Associated Cardiovascular Disease Risk
Post Liver Transplant
Site: [Methodist Specialty & Transplant Hospital; Texas Transplant Institute Liver
Disease and Transplant Program (Liver Clinic)]
  
Dear Ms. Peterson,
The above referenced study has been reviewed under expedited review (DHHS Regulation 45 CFR
46.110 and/or 21 CFR 56.110, as applicable). It is determined that this study meets minimal risk
requirements as submitted. Provisions to protect the confidentiality of subjects have also been provided
and are deemed appropriate and adequate measures for subject protection.
Expedited approval for the above referenced study is therefore granted for a period of 12 (twelve)
months, effective August 09, 2018, per 45 CFR 46.110 Categories as described below:
• •Category 5: Research involving materials (data, documents, records or specimens) that have been
collected solely for non-research purposes (such as medical treatment and/or diagnosis). 
This Approval Includes:
• Protocol version dated 8/07/2018
• Data Collection Tool
• MHS Fom P - Protocol Personnel Form
You are restricted to a maximum of 41 subjects (records).
In accord with 45 CFR 46.116(d), the requirement to obtain and document informed consent is waived for
this study. The waiver is granted after determining that: 
1. The research involves no more than minimal risk to the subjects;
2. The waiver or alteration will not adversely affect the rights and welfare of the subjects;
3. The research cannot practicably be carried out without the waiver; and
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- 2 - Generated on IRBNet
4. Due to the nature of the study, status of the study subjects, data and manner in which data will be
collected, it would not be appropriate to provide them with pertinent information after participation.
This approval expires August 9, 2019. A progress report must be submitted for continuing review
and approved by the Board prior to that date. Failure to do so by this date will result in enrollment
suspension. Further delay will result in study closure. A Progress Report form (and other forms needed
for IRB submission) can be found in the library section of the Designer page on IRBNet.
RESPONSIBILITIES OF PRINCIPAL INVESTIGATOR:
1. Report to the MHS IRB any death of a subject whether Anticipated or Unanticipated and whose
cause is related to the study or study procedures. The report must be submitted to the MHS IRB
within ten (10) working days of the investigator becoming aware of the death;
2. Report promptly to the IRB any reportable severe adverse reactions or serious problems, per IRB
Guidelines;
3. Report any significant findings that become known in the course of the research that might affect the
willingness of subjects to continue to take part;
4. Ensure that only persons formally approved by the IRB enroll subjects;
5. Submit for review and approval by the IRB all modifications to the protocol or consent form(s) prior
to the implementation of the change;
6. Submit a progress report for continuing review by the IRB. Federal regulations require that the IRB
review on-going projects no less than one year from the approval date (progress report available in
the Library in IRBNet); and
7. Notify the IRB in writing when the study has been completed and prepare a final report (Progress
Report form).
If you have any questions, please contact the IRB Office or Tara Garcia at (210) 575-4918 or
tara.garcia2@mhshealth.com. Please include your study title and reference number in all correspondence
with this office.
 
"This document has been electronically signed in accordance with all applicable regulations, and a copy is
retained within our records."
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1618 E. Helen St.
P.O.Box 245137
Tucson, AZ 85724-5137
Tel: (520) 626-6721
http://rgw.arizona.edu/compliance/home
Human Subjects
Protection Program
 
Date: September 18, 2018
Principal Investigator: Katrina Irene Peterson
Protocol Number: 1809938086
Protocol Title: Metabolic Complications and Associated Cardiovascular Disease RiskPost Liver Transplant
Level of Review: Administrative Review
Determination: Approved
IRB of Record: Methodist specialty and transplant hospital
Investigator at Site: Katrina Peterson
IRB of Record Protocol
Number: 1289067-1
Documents Reviewed Concurrently:
     Data Collection Tools:  Data Collection Instrument.docx
     HSPP Forms/Correspondence:  Advisor Confirmation Email.pdf
     HSPP Forms/Correspondence:  Confirmation for Scientific Review and Department Review.pdf
     HSPP Forms/Correspondence:  Peterson Application for Human Research (2).pdf
     HSPP Forms/Correspondence:  Peterson List of Research Personnel.pdf
     Other:  Data Use Agreement.pdf
     Other:  Peterson_Resume2018.docx
     Other Approvals and Authorizations:  COI Certification Complete for 1809938086.msg
     Other Approvals and Authorizations:  Expedited Approval Letter.pdf
     Other Approvals and Authorizations:  Form H Waiver of Alteration of HIPAA Authorization.docx
     Other Approvals and Authorizations:  Form J Waiver or Alteration of Consent.docx
     Other Approvals and Authorizations:  Form P Research Personnel.doc
     Other Approvals and Authorizations:  HIPAA Waiver Approval (1).pdf
     Other Approvals and Authorizations:  Revised MHS IRB Initial Application.docx
     Protocol:  Research Protocol MHS.DOCX
Regulatory Determinations/Comments: 
• Methodist Healthcare Designated IRB of Record: When an institution is designated IRB of record,
the UA IRB will not review the project.' The University of Arizona agrees that it will rely on the
review, approval, and continuing oversight of the institution's IRB pursuant to the terms of the
Institutional Review Board Authorization Agreement.
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• The University of Arizona maintains a Federalwide Assurance with the Office for Human
Research Protections (FWA #00004218).
• All documents referenced in this submission have been reviewed and are filed with the HSPP.
  The Principal Investigator should notify the IRB immediately of any proposed changes that
affect the LOCAL protocol and report any LOCAL unanticipated problems involving risks
to participants or others. Please refer to Guidance's Investigators Responsibility after IRB
Approval and Reporting Local Information.
• All research procedures should be conducted according to the approved protocol and the
policies and guidance of the IRB of record.
 
 
  
61 
REFERENCES 
Agarwal, A. & Prasad, G. V. R. (2016). Post-transplant dyslipidemia: Mechanisms, diagnosis, 
and treatment. World Journal of Transplantation, 6(1), 125-134.  
American Diabetes Association (2018). Statistics about diabetes. Retrieved from 
http://www.diabetes.org/diabetes-basics/statistics/?loc=db-slabnav 
Ayloo, S., Armstrong, J., Hurton, S., & Molinari, M. (2015). Obesity and liver transplantation. 
World Journal of Transplantation, 5(3), 95-101.  
Ballestri, S., Nascimbeni, F., Baldelli, E., Marrazzo, A., Romagnoli, D. & Lomardo, A. (2017). 
NAFLD as a sexual dimorphic disease: Role of gender and reproductive status in the 
development and progression of nonalcoholic fatty liver disease and inherent 
cardiovascular risk. Advances in Therapy, 34(6), 1291-1326. 
Barnard, A., Konyn, P., & Saab, S. (2016). Medical management of metabolic complications of 
liver transplant recipients. Gastroenterology and Hepatology, 12, 601-608. 
Bertot, L. C. & Adams, L. A. (2016). The natural course of non-alcoholic fatty liver disease. 
International Journal of Molecular Sciences, 17(5), 774. 
Brunault, P., Salame, E., Jaafari, N., Courtois, R., Reveillere, C., Silvain, C., . . . Ballon, N. 
(2015). Why do liver transplant patients so often become obese? Medical Hypotheses, 85, 
68-75. 
Centers for Disease Control and Prevention (2018a). Adult obesity facts. Retrieved from 
https://www.cdc.gov/obesity/data/adult.html 
Centers for Disease Control and Prevention (2018b). Adult obesity prevalence maps. Retrieved 
from https://www.cdc.gov/obesity/data/prevalence-maps.html 
Chalasani, N., Younossi, Z., Lavine, J. E., Charlton, M., Cusi, K., Rinella, M., . . . Sanyal, A. J. 
(2018). The diagnosis and management of nonalcoholic fatty liver disease: Practice 
guidance from the American Association for the Study of Liver Diseases. Hepatology, 
67(1).  
Chaney, A. J. & Heckman, M. G. (2018). The benefit of supplemental nutrition education for 
severely malnourished patients awaiting liver transplant. Progress in Transplantation, 
28(4), 390-393.  
City of San Antonio Metropolitan Health District (2017). Strategic plan January 2017 – 
December 2019. Retrieved from 
https://www.sanantonio.gov/Portals/0/Files/health/News/Reports/StrategicPlan5-27-
2017.pdf?ver=2017-05-30-162509-187 
 
  
62 
Data USA (2017). San Antonio, TX. Retrieved from https://datausa.io/profile/geo/san-antonio-
tx/#demographics 
Einarson, T. R., Acs, A., Ludwig, C., & Panton, U. H. (2018). Prevalence of cardiovascular 
disease in type 2 diabetes: A systematic literature review of scientific evidence from 
across the world in 2007-2017. Cardiovascular Diabetology, 17(83), 1-19. 
Fussner, L. A., Heimbach, J. K., Fan, C., Dierkhising, R., Coss, E., Leise, M. D., & Watt, K. D. 
(2015). Cardiovascular disease after liver transplantation: When, what, and who is at 
risk? Liver Transplantation, 21, 889-896.  
Gallegos-Orozco, J. F. & Charlton, M. R. (2017). Predictors of cardiovascular events after liver 
transplantation. Clinical Liver Disease, 21(2), 367-379.  
Glowczynska, R., Galas, M., Witkowska, A., Oldakowska-Jedynak, U., Raszeja-Wyszomirska, 
J., Krasuski, K., . . . Opolski, G. (2018). The pre-transplant profile of cardiovascular risk 
factors and its impact on long-term mortality after liver transplantation. Annals of 
Transplantation, 23, 591-597.  
Grundy, S. M., Stone, N. J., Bailey, A. L., Beam, C., Birtcher, K. K., Blumenthal, R. S., … 
Yeboah, J. (2018). 2018 guideline on the management of blood cholesterol. Journal of 
the American College of Cardiology. 
Gunn, N. T. & Shiffman, M. L. (2018). The use of liver biopsy in nonalcoholic fatty liver 
disease: When to biopsy and in whom. Clinics in Liver Disease, 28(1), 109-119. 
Hadi, H. E., Vettor, R., & Rossato, M. (2018). Vitamin E as a treatment for non-alcoholic fatty 
liver disease: Reality or myth. Antioxidants, 7(1), 12.  
Haugen, C., Holscher, C. M., Garonzik-Wang, J., Pozo, M., Warsame, F., McAdams-DeMarco, 
M., & Segev, D. L. (2018). National trends in liver transplantation in older adults. The 
American Geriatrics Society, 66, 2321-2326. 
Hejlova, I., Honsova, E., Sticova, E., Lanska, V., Hucl, T., Spicak, J., . . . Trunecka, P. (2016). 
Prevalence and risk factors of steatosis after liver transplantation and patient outcomes. 
Liver Transplantation, 22, 644-655.  
Hughes, C. (2017). Coding and documentation. Family Practice Management, 24(1), 35.  
Husing, A., Kabar, I., & Schmidt (2016). Lipids in liver transplant recipients. World Journal of 
Gastroenterology, 22(12), 3315-3324. 
Jimenez-Perez, M., Gonzalez-Grande, R., Guzman, E. O., Trillo, V. A., & Lopez, J. M. R. 
(2016). Metabolic complications in liver transplant recipients. World Journal of 
Gastroenterology, 22, 6416-6423.  
 
  
63 
Khan, R. S. & Newsome, P.N. (2016). Non-alcoholic fatty liver disease and liver transplantation. 
Metabolism, 65(8), 1208-1223. 
Konerman, M. A., Fritze, D., Weinberg, R. L., Sonneday, C. J., & Sharma, P. (2017). Incidence 
of and risk assessment for adverse cardiovascular outcomes following liver 
transplantation: A systematic review. Transplantation, 101(7), 1645-1657. 
Lindenmeyer, C. C. & McCullough, A. J. (2017). Which patients with nonalcoholic fatty liver 
disease should undergo liver biopsy. Cleveland Clinic Journal of Medicine, 84(4), 273-
275. 
Lucey, M. R., Terrault, N., Ojo, L., Hay, J. E., Neuberger, J., Blumberg, E., & Teperman, L. W. 
(2013). Long-term management of the successful adult liver transplant: 2012 practice 
guideline by the American Association for the Study of Liver Disease and the American 
Society of Transplantation. Liver Transplantation, 19, 3-26.  
Marjot, T., Sbardella, E., Moolla, A., Hazlehurst, J. M., Tan, G. D., Ainsworth, M., . . . 
Cobbhold, J. F. L. (2018). Prevalence and severity of non-alcoholic fatty liver disease are 
underestimated in clinical practice: Impact of a dedicated screening approach at a large 
university teaching hospital. Diabetic Medicine, 89-98. 
Martin, P., DiMartini, A., Feng, S., Brown, Jr., R., & Fallon, M. (2014). Evaluation for liver 
transplantation in adults: 2013 practice guideline by the American Association for the 
Study of Liver Diseases and the American Society of Transplantation. Hepatology, 59(3), 
1144-1165. 
Maurice, J. & Manousou, P. (2018). Non-alcoholic fatty liver disease. Clinical Medicine, 18(3), 
245-250. 
Methodist Physicians San Antonio (2019). Liver transplant. Retrieved from 
https://methodistphysicianpractices.com/service/liver-transplant 
Mikolasevic, I., Filipec-Kanizaj, T., Mijic, M., Jakapcic, I., Milic, S., Hrstic, I., . . . Burra, P. 
(2018). Nonalcoholic fatty liver disease and liver transplantation – Where do we stand? 
World Journal of Gastroenterology, 24(24), 1491-1506. 
Moini, M., Schilsky, M. L., & Tichy, E. M. (2015). Review on immunosuppression in liver 
transplantation. World Journal of Hepatology, 7(10), 1355-1368. 
Organ Procurement and Transplantation Network (2019). National data. Retrieved from 
https://optn.transplant.hrsa.gov/data/view-data-reports/national-data/ 
Pais, R., Barritt, A. S., Calmus, Y., Scatton, O., Runge, T., Lebray, P., . . . Conti, F. (2016). 
NAFLD and liver transplantation: Current burden and expected challenges. Journal of 
Hepatology, 65(6), 1245-1257.  
 
  
64 
Pan, J. & Fallon, M. B. (2014). Gender and racial differences in nonalcoholic fatty liver disease. 
World Journal of Hepatology, 6(5), 274-283. 
Patel, Y. A., Berg, C. L, & Moylan, C. A. (2016). Nonalcoholic fatty liver disease: Key 
considerations before and after liver transplantation. Digestive Diseases and Sciences, 61, 
1406-1416.  
Perumpail, B. J., Khan, M. A., Yoo, E. R., Cholankeril, G., Kim, D., & Ahmed, A. (2017). 
Clinical epidemiology and disease burden of nonalcoholic fatty liver disease. World 
Journal of Gastroenterology, 23(47), 8263-8276. 
Pisano, G., Fracanzani, A. L., Caccamo, L., Donato, M. F., & Fargion, S. (2016). Cardiovascular 
risk after orthotopic liver transplantation, a review of the literature and preliminary 
results of a prospective study. World Journal of Gastroenterology, 22(40): 8869-8882. 
Ratziu, V. & Marchesini, G. (2016). When the journey from obesity to cirrhosis takes an early 
start. Journal of Hepatology, 65, 249-251.  
Sanyal, R., Zarzour, J. G., Ganeshan, D. M., Bhargava, P., Lall, C. G., & Little, M. D. (2014). 
Postoperative doppler evaluation of liver transplants. Indian Journal of Radiology and 
Imaging, 24(4), 360-366. 
Scientific Registry of Transplant Recipients (2019). The STRT database overview. Retrieved 
from https://www.srtr.org/about-the-data/the-srtr-database/ 
Scientific Registry of Transplant Recipients (2018). Program summary. Retrieved from 
https://www.srtr.org/document/pdf?fileName=%5C012018_release%5CpdfPSR%5CTX
HSTX1LI201711PNEW.pdf 
Song, A. T. W., Avelin-Silva, V. I., Pecora, R. A. A., Pugliese, V., D’Albuquerque, L. A. C., & 
Abdala, E. (2014). Fifty years of experience. World Journal of Gastroenterology, 20(18), 
5363 – 5374. 
Unger, L., Merima, H., Staufer, K., Salat, A., Silberhumer, G., Hofmann, M., . . . Berlakovich, 
G. A. (2017). The post-transplant course of patients undergoing liver transplantation for 
nonalcoholic steatohepatitis versus cryptogenic cirrhosis: A retrospective case-control 
study. European Journal of Gastroenterology & Hepatology, 29(3), 309-316. 
Wang, L., Yu, S., & Chan, A. W. H. (2016). Pathology of non-alcoholic fatty liver disease. 
International Journal of Digestive Diseases, 2(1), 1-7. 
Whelton, P. K., Carey, R. M., Aronow, W. S., Casey Jr., D. E., Collins, K. J., Himmelfarb, C. D., 
. . . Wright Jr., J. T. (2018). 2017 
ACC/AHA/AAPA/ABC/ACPM/AGS/AphA/ASH/ASPC/NMA/PCNA Guideline for the 
prevention, detection, evaluation, and management of high blood pressure in adults: A 
 
  
65 
report of the American College of Cardiology/American Heart Association Task Force on 
Clinical Practice Guidelines. Hypertension, 71, e13-e115. 
doi:10.1161/HYP.0000000000000065 
World Health Organization (2019). Obesity. Retrieved from 
https://www.who.int/topics/obesity/en/ 
